Celgene Corporation, the renowned integrated global biopharmaceutical company today announced here that human placenta-derived stem cells that are ?pluripotent?, or having the ability to become different types of tissue, can be isolated with a proprietary perfusion technology from placentas so they are available for potential treatment applications. The announcement happened in an oral presentation last day at the International Conference on Stem Cells Research and Therapeutics in San Diego by Qian Ye, PhD, the Senior Scientist, at Celgene Cellular Therapeutics.
It has come to the knowledge, that the objective of the study was regarding the usage of a proprietary perfusion method to recover pluripotent stem cells from human placenta after birth, to culture them, and to characterize the cells from a surface marker and differentiation perspective. The study used those human placentas that were donated to LifebankUSA following the birth of normal, full-term pregnancies. Through a unique proprietary process that anatomically perfuses the placenta, mononucleated cells were obtained, purified, and cultured. Fluorescence activated cell sorter (FACS) analysis was used for cell surface marker characterization, and reverse transcription polymerase chain reaction (RT-PCR) for gene expression analysis.
It has been avowed, that within two to four weeks, adherent cells with fibroblast-like morphology could be grown from the placenta perfusate culture. Morphologic examination and quantitative gene analysis showed that these cells were capable of expressing morphologic features and a gene transcript, the hallmark of primitive stem cells. However, under certain culture conditions, these cells were transformed into cartilage- like and fat-like tissue.
It was the Celgene Cellular Therapeutics that first reported about its success in the isolation of placental stem cells and turned them into nerve, blood, cartilage, skin and muscle cells in 2001. Since that time, other studies have confirmed that pluripotent and multipotent placental and cord blood stem cells can be isolated. The study presented in this regard on yesterday employed a proprietary placenta perfusion method to recover the cells from placentas after birth.
Dr. Robert Hariri, the President of LifebankUSA and Celgene Cellular Therapeutics on this occasion said, ?This study contributes to a growing body of evidence that the placenta is an important and novel source of stem cells that can potentially be used for the repair of damaged or diseased tissue.? ?Demonstrating the full potential of the stem cells recovered by this novel method provides Celgene scientists with another opportunity to further stem cell research and the stem cell therapy development process,? he added.
It has come to the knowledge, that the objective of the study was regarding the usage of a proprietary perfusion method to recover pluripotent stem cells from human placenta after birth, to culture them, and to characterize the cells from a surface marker and differentiation perspective. The study used those human placentas that were donated to LifebankUSA following the birth of normal, full-term pregnancies. Through a unique proprietary process that anatomically perfuses the placenta, mononucleated cells were obtained, purified, and cultured. Fluorescence activated cell sorter (FACS) analysis was used for cell surface marker characterization, and reverse transcription polymerase chain reaction (RT-PCR) for gene expression analysis.
It has been avowed, that within two to four weeks, adherent cells with fibroblast-like morphology could be grown from the placenta perfusate culture. Morphologic examination and quantitative gene analysis showed that these cells were capable of expressing morphologic features and a gene transcript, the hallmark of primitive stem cells. However, under certain culture conditions, these cells were transformed into cartilage- like and fat-like tissue.
It was the Celgene Cellular Therapeutics that first reported about its success in the isolation of placental stem cells and turned them into nerve, blood, cartilage, skin and muscle cells in 2001. Since that time, other studies have confirmed that pluripotent and multipotent placental and cord blood stem cells can be isolated. The study presented in this regard on yesterday employed a proprietary placenta perfusion method to recover the cells from placentas after birth.
Dr. Robert Hariri, the President of LifebankUSA and Celgene Cellular Therapeutics on this occasion said, ?This study contributes to a growing body of evidence that the placenta is an important and novel source of stem cells that can potentially be used for the repair of damaged or diseased tissue.? ?Demonstrating the full potential of the stem cells recovered by this novel method provides Celgene scientists with another opportunity to further stem cell research and the stem cell therapy development process,? he added.